Safety evaluation of adenovirus type 4 and type 7 vaccine live, oral in military recruits  by Choudhry, Azhar et al.
Vaccine 34 (2016) 4558–4564Contents lists available at ScienceDirect
Vaccine
journal homepage: www.elsevier .com/locate /vaccineSafety evaluation of adenovirus type 4 and type 7 vaccine live, oral
in military recruitshttp://dx.doi.org/10.1016/j.vaccine.2016.07.033
0264-410X/ 2016 The Authors. Published by Elsevier Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
⇑ Corresponding author.
E-mail address: azhar.choudhry@tevapharm.com (A. Choudhry).Azhar Choudhry MD, MBA a,⇑, Julie Mathena MBA a, Jessica D. Albano PhD, MPHb,
Margaret Yacovone MD, MS c, Limone Collins MD c
a Teva Pharmaceuticals, Inc., 11100 Nall Ave, Overland Park, KS 66211, USA
b INC Research LLC, 1011 Ashes Drive, Wilmington, NC 28405, USA
c Immunization Healthcare Branch, Public Health Division, Defense Health Agency, 7700 Arlington Blvd, Falls Church, VA 22042, USA
a r t i c l e i n f oArticle history:
Received 29 April 2016
Received in revised form 2 July 2016
Accepted 18 July 2016
Available online 27 July 2016
Keywords:
Respiratory illness
Vaccination
Adenovirus
Retrospective
Surveillancea b s t r a c t
Before the widespread adoption of vaccination, adenovirus type 4 and type 7 were long associated with
respiratory illnesses among military recruits. When supplies were depleted and vaccination was sus-
pended in 1999 for approximately a decade, respiratory illnesses due to adenovirus infections resurged.
In March 2011, a new live, oral adenovirus vaccine was licensed by the US Food and Drug Administration
and was first universally administered to military recruits in October 2011, leading to rapid, dramatic
elimination of the disease within a few months. As part of licensure, a postmarketing study (Sentinel
Surveillance Plan) was performed to detect potential safety signals within 42 days after immunization
of military recruits. This study retrospectively evaluated possible adverse events related to vaccination
using data from the Armed Forces Health Surveillance Branch Defense Medical Surveillance System
(DMSS) database. Among 100,000 recruits who received the adenovirus vaccine, no statistically signifi-
cant greater risk of prespecified medical events was observed within 42 days after vaccination when
compared with a historical cohort of 100,000 unvaccinated recruits. In an initial statistical analysis of
International Classification of Disease, 9th Revision, Clinical Modification codes, a statistically significant
higher risk for 19 other (not prespecified) medical events occurring in 5 or more recruits was observed
among vaccinated compared with unvaccinated groups. After case record data abstraction for attribution
and validation, two events (psoriasis [21 vs 7 cases] and serum reactions [12 vs 4 cases]) occurred more
frequently in the vaccinated cohort. A causal relation of these rare events with adenovirus vaccination
could not be established given confounding factors in the DMSS, such as coadministration of other vac-
cines and incomplete or inaccurate medical information, for some recruits. Prospective surveillance
assessing these uncommon, but potentially relevant, immune-related symptoms may be beneficial in
defining potential causal association with adenovirus vaccination.
 2016 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Prior to the widespread use of adenovirus vaccine by the US
military, adenovirus type 4 and type 7 accounted for approxi-
mately 60% of respiratory illnesses observed in hospitalized mili-
tary recruits. [1,2] A live oral vaccine against adenovirus type 4
and type 7, introduced in the 1970s, was proven safe and effective,
reducing adenovirus-associated respiratory illnesses by approxi-
mately 5.5-fold [1].
Despite their efficacy, production of the vaccine by the sole
manufacturer was discontinued in 1996, leading to rationing ofthe remaining vaccine stocks until depletion in 1999 [3,4].
Surveillance during this transition period showed a resurgence in
adenovirus infections coinciding with an increase in febrile respi-
ratory illnesses among military recruits [3]. Surveillance data from
1999 to 2004 indicated a 3-fold increase in respiratory illness rates
after vaccination was discontinued, and eight deaths were attribu-
ted to adenovirus-associated respiratory disease between 1999
and 2010 [4,5]. In March 2011, a new adenovirus type 4 and type
7 vaccine live, oral, was licensed by the US Food and Drug
Administration (FDA), and universal vaccination was reinstated
for recruits in all military branches and the Coast Guard in October
2011 [6]. Within the first two years after the vaccine’s reintroduc-
tion, adenovirus-associated disease burden decreased approxi-
mately 100-fold among recruits (as reflected by a decrease from
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1000 person-weeks in 2012–2013) [6].
Clinical data from phase 1 and 3 studies with military recruits
have demonstrated that the new vaccine is safe. In a phase 1, ran-
domized double-blind, placebo-controlled study (N = 58), the most
common adverse events (AEs) in the vaccinated group were nasal
congestion (33%), cough (33%), sore throat (27%), headache (20%),
abdominal pain (17%), arthralgia (13%), nausea (13%), and diarrhea
(13%) [7]. The overall frequencies of AEs were similar to those in
the placebo-treated arm [7]. In a phase 3, multicenter, randomized,
double-blind, placebo-controlled study with military recruits
(N = 4040), the incidence of AEs was comparable between vaccine
and placebo arms [8]. No discontinuations due to AEs and no
deaths were reported during the study [8]. Common (P10%) AEs
associated with vaccination included upper respiratory tract infec-
tions (39%), headache (41%), nasal congestion (24%), pharyngo-
laryngeal pain (25%), cough (23%), arthralgia (26%), nausea (18%),
abdominal pain (16%), and diarrhea (13%) [8]. Serious AEs were
seen in 1% of both the vaccine and placebo arms. The most com-
mon serious AEs were psychiatric disorders and traumatic injuries.
The FDA mandated a postmarketing study (termed the Sentinel
Surveillance Plan) to detect potential safety signals in military
recruits exposed to this vaccine. The objective of this study was
to assess the risk of medical events of interest or other events
potentially related to administration of adenovirus type 4 and type
7 vaccine live, oral in a healthy US military population.2. Methods
2.1. Study design
This study retrospectively evaluated possible AEs related to vac-
cination with adenovirus type 4 and type 7 vaccine live, oral using
data coded based on the International Classification of Disease, 9th
Revision, Clinical Modification (ICD-9-CM) and maintained as part
of the Defense Medical Surveillance System (DMSS) database. The
DMSS contains longitudinal health records for US military person-
nel including current and historical data on diseases, medical
events, vaccination, and deployment history [9]. AE data were col-
lected for the vaccinated (hereafter referred to as exposed) cohort
and a historical unvaccinated (hereafter referred to as unexposed)
cohort of recruits from the previous year attending specific training
sites for the Army (Fort Benning, GA; Fort Jackson, SC; Fort Leonard
Wood, MO; Fort Sill, OK), Navy (Great Lakes Naval Training Center,
Great Lakes, IL), Marine Corps (Parris Island, SC; San Diego, CA), and
Air Force (Lackland Air Force Base, San Antonio, TX). The study was
conducted under an institutional review board–granted waiver of
informed consent.
2.2. Subjects
The exposed cohort consisted of healthy military recruits,
17–50 years of age, who received the live adenovirus type 4 and
type 7 vaccine at the initiation of basic training at one of the spec-
ified training sites. The unexposed cohort comprised historically
matched recruits who attended the same training site location dur-
ing the same month in the previous year; these individuals had the
same vaccine requirements as the exposed group but did not
receive the adenovirus vaccine.
2.3. Routine vaccinations
Adenovirus type 4 and type 7 vaccine, live, oral contains a lyo-
philized formulation of selected wild-type virus, with no fewer
than 32,000 tissue-culture infective doses per enteric-coatedtablet. Vaccine was administered orally as two tablets (one tablet
each of type 4 and type 7), swallowed whole without chewing, at
the beginning of basic training. The following additional manda-
tory vaccines were routinely administered to military recruits
without contraindications within their first week of basic training
(mandatory vaccines may vary by installation): meningococcal,
inactivated polio, tetanus-diphtheria-acellular pertussis, influenza
(inactivated or live attenuated), pneumococcal (when indicated
per Service policy), typhoid inactivated (when indicated per Ser-
vice policy), and yellow fever (when indicated per Service policy).
Recruits testing seronegative for measles, rubella, varicella, or hep-
atitis A or B were also vaccinated against these viruses. In addition,
female recruits were offered the human papillomavirus vaccine per
Service policy.
2.4. Data collection and extraction (Fig. 1)
Adverse medical events occurring among recruits were identi-
fied through routine health encounters and were coded by the
health personnel at the training sites according to ICD-9-CM and
entered into the DMSS. Reported events that occurred within
42 days following administration of adenovirus vaccine or initial
mandatory vaccines during basic training were collected for each
individual in the exposed and unexposed cohorts.
Adverse medical events were classified as ‘‘prespecified AEs of
interest” or ‘‘cohort-associated AEs.” Prespecified AEs of interest
were determined by the study sponsor (including the Department
of Defense) in discussion with the FDA prior to study initiation as
medically important and potentially related to adenovirus vaccina-
tion (Table 1). Cohort-associated AEs were defined as any events
(prespecified or otherwise) occurring at a statistically significant
higher incidence rate (as determined using the Poisson regression
model with two-tailed statistical testing conducted at a 5% signif-
icance level) in the exposed cohort compared with the unexposed
cohort. Because of the nonspecific nature of some cohort-
associated event codes at the ICM-9-CM 3-digit classification level,
data were also collected at the 4- to 5-digit subcode level for all
cohort-associated event codes that reached statistical significance
at the 3-digit level. Cohort-associated events were captured using
only data entered into the primary diagnostic code position for a
particular health encounter (eg, events coded in 2nd to 8th diag-
nostic code positions were not considered).
The contract research organization (CRO) medical monitor con-
ducted a medical review to determine if there was a plausible bio-
logical relationship between each potential cohort-associated ICD-
9-CM event code and the vaccine. The scientific review committee
(SRC) conducted an independent review and made recommenda-
tions for the inclusion of selected cohort-associated medical event
codes as emergent events of interest, defined as possibly related to
the adenovirus vaccination, unexpected, and clinically important.
The CRO medical monitor, in consultation with the Immuniza-
tion Healthcare Branch at the Defense Health Agency further vali-
dated prespecified medical events and/or emergent events of
interest by reviewing abstracted available medically relevant infor-
mation from the individual records of subjects who experienced
the events using a standardized data-abstraction form. During
abstraction, data were captured using ICD-9-CM event codes listed
in any diagnostic code position. Data (personal identifiable infor-
mation redacted) abstracted from medical records included, as
available, details of each report of the medical event of interest;
hospital admissions related to the event; acute and chronic condi-
tions; AEs occurring within 42 days of vaccination, excluding pre-
specified events of interest; alcohol, recreational drug, and
tobacco use; and use of other medications and nondrug therapies.
The completed abstraction forms were reviewed and approved by
the Department of Defense principal investigator to ensure
Fig. 1. Flow of information for medical event endpoints. Note: A validated event is one whose ICD-9-CM code was found in the subject’s electronic health record and evidence
supported the occurrence of the event.
Table 1
Prespecified medical events of interest investigated as possibly related to a live
adenovirus vaccine.
ICD-9-CM
code
Medical event of interest
242 Thyrotoxicosis with or without goiter
242.0 Toxic diffuse goiter
323.5 Encephalitis, immunization
323.51 Encephalitis, encephalomyelitis, immunization
345.9 Epilepsy, unspecified
357.0 Acute infective polyneuritis
420 Acute pericarditis
480 Viral pneumonia
480.0 Pneumonia due to adenovirus
486 Pneumonia, organism unspecified
518.82 Other pulmonary insufficiency, NEC
560.0 Intussusception
695.1 Erythema multiforme
780.2 Syncope and collapse
782 Symptoms involving skin and other integumentary tissue
782.1 Rash and other nonspecific skin eruption (limited to
hospitalization)
977.9 Poisoning by unspecified drug or medicinal substance
995.0 Other anaphylactic shock, NEC
995.2 Other and unspecified adverse effect of drug, medicinal and
biological substance (due) to correct medicinal substance
properly administered
999.4 Anaphylactic shock due to serum, NEC
ICD-9-CM = International Classification of Disease, 9th Revision, Clinical Modifica-
tion; NEC = not elsewhere classified.
Table 2
Demographics of cohorts at screening.
Exposed cohorta n (%) Unexposed cohorta n (%)
Gender
Female 15,973 (16) 16,518 (17)
Male 84,027 (84) 83,482 (84)
Race
White 62,879 (63) 62,530 (63)
Black 16,591 (17) 15,418 (15)
Hispanic 10,794 (11) 11,740 (12)
Asian/Pacific Islander 2913 (3) 3026 (3)
American Indian 946 (<1) 748 (<1)
Unknown/Other 5877 (6) 6538 (7)
Age at first vaccination (years)
17 41 (<1) 60 (<1)
18 11,945 (12) 12,078 (12)
19–24 76,851 (77) 75,466 (76)
25–29 9272 (9) 9694 (10)
30–34 1643 (2) 1861 (2)
35–39 229 (<1) 676 (<1)
40–50 19 (<1) 165 (<1)
Branch of service
Air Force 21,813 (22) 21,813 (22)
Army 40,538 (41) 40,538 (41)
Marine Corps 19,662 (20) 19,662 (20)
Navy 17,987 (18) 17,987 (18)
a Exposed and unexposed cohort each has a total of 100,000 recruits.
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abstracted data before release. For certain codes where large num-
bers of events were reported, a random sample of the correspond-
ing records was abstracted per recommendation by the SRC.
Following abstraction, some events were rejected as related to vac-
cination for any of the following reasons: (1) the event occurred
outside of the relevant exposure window; (2) confirmed laboratory
findings indicated that the medical event occurred prior to vacci-
nation; (3) the event was due to a preexisting condition without
evidence of an acute event related to vaccination; and, (4) there
was a lack of documentation for a clinical syndrome or expected
treatment consistent with the event term.2.5. Statistical methods
The final cumulative analysis was planned and performed after
100,000 matched recruits had accrued in the exposed cohort. A
sample size of 200,000 (100,000 per cohort) was expected to pro-
vide more than 80% power to detect a 2-fold increase in preva-
lence, assuming an event was present in at least 0.024% of the
unexposed cohort, and a two-sided alpha of 0.05.
Analyses of prespecified and emergent medical events of inter-
est were conducted by calculating the incidence rate for each
cohort and determining the risk ratio. Incidence rate was defined
as the total number of subjects experiencing a specific event code
for the first time during the study period divided by person-years
at risk among recruits over the same period. Person-years were
estimated using the number of recruits and 42 days following
Table 3
Incidence rates, risk ratios, and 95% confidence interval for prespecified medical events of interest among healthy military recruits vaccinated with adenovirus type 4 and type 7
vaccine.
ICD-9-CM code Description Exposed cohort
n (IR/100,000 P-Y)
Unexposed cohort
n (IR/100,000 P-Y)
RR 95% CI
Total number of prespecified events 3474 4789 0.7254 0.69–0.76
242 Thyrotoxicosis 11
(95.66)
10
(86.96)
1.10 0.47–2.59
242.0 Toxic diffuse goiter 0 0 – –
323.5 Encephalitis, immunization 1
(8.70)
1
(8.70)
1.00 0.06–15.99
323.51 Encephalitis, encephalomyelitis, immunization 0 0 – –
345.9 Epilepsy 18
(156.54)
35
(304.37)
0.51 0.29–0.91
357.0 Acute infective polyneuritis 3
(26.09)
7
(60.87)
0.43 0.11–1.66
420 Acute pericarditis 2
(17.39)
3
(26.09)
0.67 0.11–3.99
480.0 Pneumonia, adenovirus 0 10
(86.96)
– –
480 Viral pneumonia 0 24
(208.71)
– –
486 Pneumonia, unspecified 1432
(12453.26)
2648
(23028.09)
0.54 0.51–0.58
518.82 Other pulmonary insufficiency 3
(26.09)
4
(34.79)
0.75 0.17–3.35
560.0 Intussusception 1
(8.70)
1
(8.70)
1.00 0.06–15.99
695.1 Erythema multiforme 0 0 – –
780.2 Syncope 394
(3426.38)
454
(3948.17)
0.87 0.76–0.99
782 Symptoms involving skin 1459
(12688.06)
1437
(12496.74)
1.02 0.94–1.09
782.1 Rash inpatient 2
(17.39)
10
(86.96)
0.20 0.04–0.91
977.9 Poisoning, unspecified 6
(52.18)
3
(26.09)
2.00 0.50–8.00
995.0 Anaphylactic shock, other 46
(400.03)
29
(252.20)
1.59 1.00–2.52
995.2 Adverse effect of drug, unspecified 96
(834.86)
110
(956.60)
0.87 0.66–1.15
999.4 Anaphylactic shock, serum 0 3
(26.09)
– –
CI = confidence interval; ICD-9-CM = International Classification of Disease, 9th Revision, Clinical Modification.
Incidence rate (IR) per 100,000 person-years (P-Y) of exposure (IR/100,000 P-Y) = event ⁄ 100,000/P-Y of exposure; risk ratio (RR) = IR exposed/IR unexposed.
Event codes listed in bold were selected for abstraction investigation as emergent events of interest.
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as the ratio of the exposed versus unexposed incidence rates.
Cohort-associated events were identified using a Poisson regres-
sion model with two-tailed statistical testing conducted at a 5%
significance level.3. Results
3.1. Study subjects
Adenovirus vaccination was begun on October 24, 2011, and the
final exposed recruit was vaccinated on October 5, 2012. Data from
a total of 200,000 recruits (100,000 in each cohort) were evaluated
for this study, with an estimated 11,499 person-years for each
cohort.
The demographic characteristics were similar for the exposed
and unexposed cohorts, indicating that the two groups were com-
parable (Table 2). In both groups, 84% of subjects were male; distri-
bution by race/ethnicity was also similar between the exposed and
unexposed cohorts. Ages at first vaccination ranged from 17 to
50 years. The Army accounted for the greatest proportion of study
subjects in each cohort, followed by the Air Force, the Marine
Corps, and the Navy.3.2. Prespecified medical events of interest
A total of 3474 and 4789 prespecified medical events of interest
(including ICD-9-CM event codes listed in any diagnostic code
position) were experienced by the exposed and unexposed cohorts,
respectively (Table 3). None of the prespecified medical events was
found to be statistically more frequent in the exposed group, com-
pared to the unexposed group. A significant reduction in risk was
observed in the vaccinated cohort for epilepsy, pneumonia (organ-
ism unspecified), syncope and collapse, and rash and other non-
specific skin eruption (limited to hospitalization). According to
protocol, however, these cases were not verified by abstraction
because of the reduced risk associated with these events. The
reduction in risk could not be calculated for viral pneumonia,
pneumonia due to adenovirus, or anaphylactic shock due to serum,
because no cases were reported in the exposed cohort.
A total of 103 patient cases were abstracted, including 59 in the
exposed cohort and 44 in the unexposed (Table 4). In addition,
despite the lack of statistically significant findings, medical records
for seven codes of rare and/or serious eventswere recommended for
abstraction. Abstraction of these seven events identified four that
were possibly related to adenovirus vaccination: 323.52 (myelitis,
n = 1), 420.9 (pericarditis, n = 1), 357.0 (acute infective polyneuritis,
n = 2), and995.0 (other anaphylactic shock, not elsewhere classified,
Table 4
Sampling strategy and number of completed abstractions for prespecified and emergent medical events of interest.
ICD-9-
CM code
Description Sampling Strategy Exposed Cohort Unexposed Cohort
Number of Completed
Abstractions
Number
Validated
Number
Possibly
Related
Number of Completed
Abstractions
Number
Validated
Prespecified medical events of interest
323.5 Encephalitis, immunization All 1 1 1 1 0
323.51 Encephalitis,
encephalomyelitis,
immunization
All 0 0 0 0 0
357.0 Acute infective polyneuritis All 3 2 2 7 6
420.9 Acute pericarditis All 2 1 1 3 0
560.0 Intussusception All 1 0 0 1 1
977.9 Poisoning, unspecified All 6 6 0 3 3
995.0 Anaphylactic shock, other All 46 42 3 29 23
Emergent events of interest
070.30 Viral hepatitis B All exposed 20 20 0 n/a n/a
282.2 Anemias due to disorders of
glutathione
10% random sample of
Lackland cases
41 2 0 18 0
282.5 Sickle cell trait 10% random sample of
Lackland cases
25 25 0 9 9
285.9 Anemia, unspecified 10% random sample of
Great Lakes cases
21 11 0 5 1
447.6 Arteritis, unspecified All 43 0 0 14 0
696.1 Other psoriasis All 22 21 8 9 7
999 Complications of medical
care, NEC
All 51 12 13a 16 4
ICD-9-CM = International Classification of Disease, 9th Revision, Clinical Modification; n/a = not available; NEC = not elsewhere classified.
a Includes 5 events validated by medical review.
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tered and could not be ruled out as having contributed to the events.
The data from the abstractions did not indicate any definitive
biological or clinical associations with adenovirus vaccination.3.3. Cohort-associated medical events
There were 19 cohort-associated medical events with statisti-
cally significant higher risk ratios in the exposed cohort versus
the unexposed cohort described at the 3-digit ICD-9-CM code level
and the 4- and 5-digit subcode levels (Table 5). Based on
SRC review of the data and medical evaluations, sevenTable 5
Risk ratios for statistically significant 4- and 5-digit subcodes of cohort-associated medical
vaccine.
ICD-9-CM code Description
070.30 Viral hepatitis B without hepatic coma acute
133.0 Scabies
282.2 Anemias due to disorders of glutathione met
282.5 Sickle-cell trait
285.9 Anemia unspecified
300.9 Unspecified nonpsychotic mental disorder
301.9 Unspecified personality disorder
310.2 Postconcussion syndrome
380.4 Impacted cerumen
447.6 Arteritis unspecified
472.0 Chronic rhinitis
564.00 Unspecified constipation
564.01 Slow transit constipation
565.0 Anal fissure
696.1 Other psoriasis and similar disorders
704.8 Other specified diseases of hair and hair follicle
706.1 Other acne
737.30 Scoliosis (and kyphoscoliosis) idiopathic
739.2 Nonallopathic lesions of thoracic region, NEC
CI = confidence interval; ICD-9-CM = International Classification of Disease, 9th Revision
Event codes listed in bold were selected for investigation as emergent events of interescohort-associated events were selected as emergent events of
interest for further investigation and abstraction (Table 6).3.4. Emergent events of interest
A total of 1624 and 974 emergent events of interest in seven
codes were experienced by the exposed and unexposed cohorts,
respectively. Most events were recorded at Lackland Air Force Base
and Great Lakes Naval Training Center. Medical information
related to these events from 292 subjects was abstracted for vali-
dation including 221 from the exposed cohort and 71 from the
unexposed cohort. In the case of three ICD-9-CM events thatevents among healthy military recruits vaccinated with adenovirus type 4 and type 7
RR (95% CI)
or unspecified without hepatitis delta 4.00 (1.50–10.66)
1.92 (1.37–2.70)
abolism 1.77 (1.53–2.04)
1.82 (1.53–2.16)
2.03 (1.68–2.45)
1.45 (1.09–1.94)
1.95 (1.17–3.27)
2.56 (1.18–5.52)
1.34 (1.10–1.63)
3.07 (1.68–5.62)
1.27 (1.04–1.55)
1.24 (1.12–1.37)
3.20 (1.17–8.74)
1.58 (1.04–2.40)
2.44 (1.13–5.31)
s 1.65 (1.55–1.76)
1.38 (1.18–1.63)
1.58 (1.15–2.19)
2.38 (1.04–5.43)
, Clinical Modification; NEC = not elsewhere classified; RR = risk ratio.
t.
Table 6
Incidence rates, risk ratios, and 95% confidence intervals for emergent medical events of interest among healthy military recruits vaccinated with adenovirus type 4 and type 7
vaccine.
ICD-9-CM code Description Military branch Exposed cohort n
(IR/100,000 P-Y)
Unexposed cohort n
(IR/100,000 P-Y)
RR 95% CI
070.30 Viral hepatitis B Overall 21 (182.62) 6 (52.18) 3.50 1.41–8.67
Air Force 0 1 (39.86) – –
Army 0 0 – –
Marine Corps 5 (221.15) 3 (132.69) 1.67 0.40–6.97
Navy 16 (773.57) 2 (96.70) 8.00 1.84–34.79
282.2 Anemias due to disorders of
glutathione metabolism
Overall 540 (4696.07) 308 (2678.50) 1.75 1.52–2.02
Air Force 413 (16465.53) 176 (7016.79) 2.35 1.97–2.80
Army 1 (21.45) 0 – –
Marine Corps 96 (4246.04) 98 (4334.50) 0.98 0.74–1.30
Navy 30 (1450.45) 34 (1643.85) 0.88 0.54–1.44
282.5 Sickle cell trait Overall 384 (3339.43) 218 (1895.82) 1.76 1.49–2.08
Air Force 267 (10644.78) 103 (4106.41) 2.59 2.07–3.25
Army 1 (21.45) 0 – –
Marine Corps 76 (3361.45) 87 (3847.98) 0.87 0.64–1.19
Navy 40 (1933.94) 28 (1353.76) 1.43 0.88–2.32
285.9 Anemia, unspecified Overall 539 (4687.38) 391 (3400.30) 1.38 1.21–1.57
Air Force 70 (2790.77) 59 (2352.22) 1.19 0.84–1.68
Army 171 (3668.38) 198 (4247.60) 0.86 0.70–1.06
Marine Corps 33 (1459.58) 53 (2344.17) 0.62 0.40–0.96
Navy 265 (12812.33) 81 (3916.22) 3.27 2.55–4.20
447.6 Arteritis, unspecified Overall 47 (408.73) 17 (147.84) 2.76 1.59–4.81
Air Force 4 (159.47) 0 – –
Army 0 1 (21.45) – –
Marine Corps 38 (1680.73) 15 (663.44) 2.53 1.39–4.61
Navy 5 (241.74) 1 (48.35) 5.00 0.58–42.80
696.1 Other psoriasis Overall 32 (278.29) 13 (113.05) 2.46 1.29–4.69
Air Force 4 (159.47) 1 (39.87) 4.00 0.45–35.79
Army 13 (278.88) 7 (150.17) 1.86 0.74–4.65
Marine Corps 7 (309.61) 1 (44.23) 7.00 0.86–56.90
Navy 8 (386.79) 4 (193.39) 2.00 0.60–6.64
999 Complications of medical
care, NEC
Overall 61 (530.48) 21 (182.63) 2.90 1.77–4.77
Air Force 20 (797.36) 4 (159.47) 5.00 1.71–14.63
Army 15 (321.79) 8 (171.62) 1.88 0.80–4.42
Marine Corps 3 (132.69) 3 (132.69) 1.00 0.20–4.95
Navy 23 (1112.01) 6 (290.09) 3.83 1.56–9.41
CI = confidence interval; ICD-9-CM = International Classification of Disease, 9th Revision, Clinical Modification; NEC = not elsewhere classified.
Incidence rate (IR) per 100,000 person-years (P-Y) of exposure (IR/100,000 P-Y) = event ⁄ 100,000/P-Y of exposure; risk ratio (RR) = IR exposed/IR unexposed.
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dom sampling of code 282.2 (anemias due to disorders of glu-
tathione), 282.5 (sickle cell trait), and 285.9 (anemia unspecified)
was performed on subjects from the Lackland Air Force Base and
Great Lakes Naval Training Center (see Table 6 for events by base).
A summary of the cases validated and considered related is pre-
sented in Table 4. Among the validated events, two event codes
(696.1 [other psoriasis] and 999 [complications of medical care,
not elsewhere classified]) were found to be possibly related to ade-
novirus vaccination. Among the 21 validated cases with code 696.1
in the exposed cohort, eight were assessed as possibly related to
vaccination. Among the 13 cases with code 999 and assessed as
related in the exposed cohort, five were validated; these included
four cases with subcode 999.52 (other serum reaction due to vac-
cination) and one with subcode 999.59 (other serum reaction). The
coding for the eight remaining cases was not supported by event
details and was not validated. No definitive biological or clinical
association was established between the data from the abstrac-
tions and adenovirus vaccination.
4. Discussion and conclusion
A statistically significant higher risk for 19 medical event codes
was detected in the DMSS database among recruits who received
the adenovirus type 4 and type 7 vaccine (exposed) compared withunvaccinated (unexposed) recruits. None of the prespecified med-
ical event codes was found to be statistically more frequent in the
exposed cohort than in the unexposed cohort, although anaphylac-
tic shock (code 995.0) approached significance (risk ratio = 1.59,
95% confidence interval 1.00–2.52). For most of the cohort-
associated events, the SRC determined that there was no biologi-
cally plausible explanation for the increased frequency in the vac-
cinated cohort. In general, these events were associated with
factors related to demography (eg, preponderance of an event by
gender or race) and/or geography (eg, concentration of an event
at a particular military base). However, seven events were consid-
ered emergent events of interest and six were validated through
abstraction of medical records. Of the six validated events, only
two (696.1-psoriasis and 999.5-serum reactions) had events that
were considered possibly related to vaccination. Despite the statis-
tically significant association between these event codes and vac-
cine exposure, the true relationship between the occurrence of
the event and administration of the adenovirus vaccine cannot
be evaluated based on the statistical results alone.
The retrospective nature of this study limits interpretation of
the relationship between the adenovirus vaccine and the few
events that occurred during the 42-day postvaccination period.
The military recruit population, by its nature, limits the impact
of confounding variables such as age and health status. Variability
of reporting and differences in the experience and training of
4564 A. Choudhry et al. / Vaccine 34 (2016) 4558–4564medical personnel at the basic training sites, as well as limitations
of the DMSS database such as loss to follow-up due to discharge
from the military, reduce the ability to distinguish a genuine safety
signal associated with the adenovirus vaccine from other con-
tributing factors.
For these reasons, the potential causes of the observed increases
in psoriasis, anaphylaxis, and other hypersensitivity reactions are
unclear. Prospective surveillance assessing these uncommon, but
potentially relevant, immune-related symptoms may be beneficial
in defining potential causal association with adenovirus
vaccination.
It should be highlighted that, subsequent to the institution of
adenovirus vaccination and conduct of this study, US military
investigators have also noted a reduction in adenovirus-
associated respiratory illnesses; these findings are consistent with
the beneficial effects described in earlier reports [1,3,4,6].
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